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Background: Liver perfusates exhibit theoretical advantages regarding the discovery of disease biomarkers because
they contain proteins that readily enter the blood-stream, and perfusion preserves the disease state in its natural
context. The purpose of the study is to explore the value of liver perfusate proteome in the biomarker discovery of
liver diseases.
Results: In this study, 86 differentially expressed proteins were identified in perfusates from isolated rat livers
metastasized by Walker-256 tumor cells. Among these proteins, 27 were predicted to be secreted, and 59 were
intracellular or membrane proteins. Most of the secretory proteins (70.4%) were decreased in metastasized liver
perfusates. The main canonical ingenuity pathway to which these secretory proteins belonged was acute phase
response, which indicated that the liver-associated immune reaction was damaged by the metastasis. In contrast,
most of the intracellular or membrane proteins (86.4%) exhibited higher relative abundances in the metastasized
liver perfusates. Some of these proteins, including Rpl21, Atic, Eif3s2, Echs1, Eps15 and Ywhab, have previously been
reported to be involved in cancer genesis and progression. As a member of the 14-3-3 protein family, Ywhab plays
a key role in cellular proliferation and oncogenic transformation and has been reported to be involved in the
development of breast cancer. Its abundance was elevated by 3.5-fold in the metastasized perfusates. Validation by
Western blotting revealed a 3.7-fold increase in the abundance of this protein in metastasized plasma.
Conclusions: These results show that perfusate proteome can be used as an alternative initial resource for
biomarker identification, which ultimately requires validation in serum.
Keywords: Liver perfusate proteome, Biomarker discovery, Liver metastasis, YwhabBackground
Biomarkers play a pivotal role in disease screening, diag-
nosis, therapeutic monitoring and prognosis. Because
most biomarkers used in the clinical setting are not sat-
isfactory due to their limited specificity and sensitivity
[1], an enormous effort has been made to screen and
characterize new disease biomarkers during the past several
decades. Recently, advances in proteomic technology, with
high-throughput as its characteristics, have presented new
possibilities to detect disease biomarkers.
Two strategies are routinely employed in current
proteomics-based approaches for biomarker discovery* Correspondence: gaoyouhe@pumc.edu.cn
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reproduction in any medium, provided the or[1]. The first characterizes differential protein expression
patterns by comparing serum/plasma from animal models
or patients with samples from normal controls. The second
compares diseased tissues/cells with their normal counter-
parts. Despite the unique advantages of the first strategy,
the extremely complexity of blood presents a significant
challenge for the detection of useful potential biomarkers
[1,2]. Disease-specific proteins can be characterized rela-
tively more easily by the second strategy. However, most of
these proteins remain within the cell and do not enter the
bloodstream, which makes them unavailable for measure-
ment via routine blood assays in a clinical setting.
Perfusates contain secretory proteins, membrane pro-
teins and intracellular proteins released by an isolated per-
fused organ [3]. Because perfusates pass through the same
vascular systems in the organ as does the blood, in theory,
perfusate proteins can easily enter into the bloodstream
and be detected via routine blood assays. Additionally, theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Rat weight decreased after tumor inoculation. The
average weight of the tumor-inoculated rats (179.4 g) decreased
significantly compared to the average weight of control rats












Figure 2 The degree of liver injury caused by metastasis was
recovered on day 12. The level of alanine aminotransferase (ALT) in
the serum was used as a marker of liver injury. The ALT levels
increased to the maximum level on the 6th day (Day 6) after
inoculation and returned to the control level on the 12th day
(Day 12). On the 3rd (Day 3) and 6th day (Day 6), the ALT levels in
the model rats were significantly higher than in the control rats,
p < 0.05(*), (n = 3 for each group).
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relatively intact during perfusion, which preserves the dis-
ease state more naturally compared to assays performed
at the tissue or cellular level. Therefore, perfusates have
the innate advantages in discovery of disease biomarkers.
Perfusates from isolated rat hearts during reperfusion
were collected after brief periods of ischemia, and some
known clinical biomarkers for myocardial ischemia were
identified [4].
The isolated perfused rat liver (IPRL) model was first
introduced by Claude Bernard in 1855. It is a widely
employed physiological model for studying liver functions
[5,6]. In our previous work, the IPRL model was combined
with mass spectrometry to study the liver secretome at
the organ level [3]. In the current study, perfusates were
collected from rat livers metastasized by Walker-256 cells
[7-9]. Eighty-six differentially expressed perfusate proteins
were identified and various important proteins related
to liver metastasis were identified, which indicates the
value of these perfusates for biomarker discovery. To
our knowledge, there has not been a study on differential
protein expression in the perfusates from metastasized
organs aimed at biomarker discovery.
Results and discussion
Establishment of the liver metastasis model
Metastasized cancers can form in the liver after inoculation
of the spleen with cancer cells because the liver collects the
blood from the spleen. In this study, the model of liver me-
tastasis was produced via inoculation of Walker-256 tumor
cells into male SD rat spleens, as described previously [10].
On the sixth day after inoculation, tumor tubercles were
observed in the spleen (Additional file 1: Image 1). On the
ninth day, metastasized tubercles were detected in the liver
under visual or microscopic inspection (Additional file 1:
Images 2 and 3).
The average weight of inoculated rats was much lower
than the controls
The average weight of the tumor-inoculated rats was much
lower than that of the control rats (Figure 1 and Additional
file 1: Table S1). The recorded weights were consistent with
those reported in previous studies [8,9], which showed that
Walker-256 tumor cells induce a cachectic state.
The 11-13th day after inoculation was selected as the time-
point for perfusion
It was shown by the preliminary study that metastasis
induced liver damage and made more intracellular pro-
teins released into the perfusates of metastasized livers.
These proteins were more readily identified as differen-
tially expressed proteins by proteomic analysis. In order to
discover candidate biomarkers related to liver metastasis,
we tried to reduce the effect of metastasis-induced liverdamage. So serum alanine aminotransferase (ALT) levels
were applied to monitor the damage and to find a time-
point when the damage recovered to the normal control
level. In Figure 2, ALT levels increased to the maximum
level on the 6th day after inoculation and returned to
the control level on the 12th day. Therefore, to discover
more candidate biomarkers related to metastasis, the period
from the 11-13th day was selected as the time-point
for perfusion.
Serum contamination was low in the perfusates
Because immunoglobulins are high-abundance proteins
in the serum and are not secreted by the liver [11-14],
the amount of immunoglobulins in perfusates can reflect
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chosen as an indicator of serum contamination in the
perfusates. The IgG level, as shown in Additional file 1:
Figure S1, indicated that serum contamination was at a
very low level.
The perfusates showed a different protein composition
compared to liver cytosol extracts
Figure 3 shows that the SDS-PAGE patterns were sig-
nificantly different between the perfusate and liver
cytosolic extract. Many high-abundance cytosolic proteins
(black arrows) were not present in the perfusates, whereas
some proteins were enriched in perfusates (white arrows).Figure 3 The perfusates presented a different protein composition
compared to liver cytosol extracts. Eight micrograms of protein from
the perfusate and cytosol mixturesa from both the model and control
rats was loaded onto the gel, and the gel was subsequently
silver-stained. Substantial differences were detected in the perfusate and
cytosol. Many high-abundance cytosolic proteins (black arrows) were not
observed in the perfusates, whereas some proteins were enriched in
perfusates (white arrows). M-L: Liver cytosol mixture from the model rats.
C-L: Liver cytosol mixture from the control rats. M-P: Perfusate mixture
from the model rats. C-P: Perfusate mixture from the control rats. a. The
cytosol mixture was prepared according to our previous work [3]. Briefly,
the perfused rat livers were snap-frozen with liquid nitrogen, and then
ground into a powder with a pestle. The liver tissue powder was
suspended in 40 mM Tris buffer on ice, followed by centrifugation at
12000 g for 30 minutes at 4°C. The supernatants were collected as liver
cytosol extracts. The cytosol mixture was prepared by pooling liver
cytosolic extracts from five model or control rats.Proteomic profiling of the perfusates
An online SCX-RPLC-MS/MS analysis was performed to
identify the proteins in the perfusates from the model
and control rats. Five technical replicate analyses were
conducted for each pooled perfusate sample. Additional
file 1: Table S2 lists proteins numbers and total spectral
counts identified in each replicate analysis, with probabil-
ities >0.9, as calculated by ProteinProphet. The average
numbers of proteins identified in the model and control
perfusates mixture were 771 and 674, respectively. The
average of the total spectral counts identified in the model
perfusate mixture was 16,222, which was slightly less than
the 19,241 total spectral counts identified in the control
perfusate mixture. Considering this inconsistency, spectral
count weights were used to estimate the relative protein
abundances in the perfusates.
Differential protein expression in the perfusates
The SCW was used to estimate the relative protein
abundances in the samples. The difference of each protein’s
SCW between the model and control rats was analyzed for
statistical significance by Student’s t-test. A p-value <0.01
was set as a cut-off. To increase the credibility of protein
identification and quantification, three strict criteria were
used to select differentially expressed proteins (see details
in the Experimental Procedures). A total of 59 proteins
showed an increased relative abundance, and 27 proteins
presented a decreased relative abundance in the model
perfusates (Additional file 2: Table S3).
SignalP software is routinely used to predict secretory
proteins [15]. SignalP can predict the N-terminal signal
peptide contained in classically secreted proteins. Among
the 86 differentially expressed proteins, 27 (31.4%) were
predicted to be secreted, and 59 (68.6%) were considered
non-secretory (intracellular or membrane proteins).
Functional analysis of the differentially expressed
proteins associated with cancer metastasis
Functional analysis of these differentially expressed proteins
was performed by the Ingenuity Pathway Analysis
(IPA) tool (http://www.ingenuity.com/, Ingenuity Systems,
Redwood City, CA, USA). This analysis was focused on the
pathways and disease mechanisms in which the proteins
are expected to be involved. Secretory and non-secretory
proteins were analyzed respectively.
Liver-associated immune function was suppressed by
metastasis
As shown in Figure 4A, the Ingenuity Canonical Pathway
in which the greatest number of secretory proteins partici-
pated was acute phase response signaling. The acute phase
response is a well-known liver function that plays an im-
portant role in immune defense. The perfusate proteins
involved in this pathway included TTR, MBL2, FN1, CRP
Figure 4 Functional analysis of the differentially expressed proteins in perfusates. A. the Ingenuity Canonical Pathway in which the
greatest number of secretory proteins participated was acute phase response signaling. B. the main diseases in which the non-secretory proteins
participated were liver hyperplasia/hyper-proliferation, liver hepatitis, liver steatohepatitis, liver steatosis and hepatocellular carcinoma.
Zhang et al. Proteome Science 2013, 11:37 Page 4 of 8
http://www.proteomesci.com/content/11/1/37and SERPINF1. Most of these proteins showed a de-
creased relative abundance in metastasized perfusates
(Additional file 2: Table S3), which indicated that the
liver-associated immune function was damaged by the
metastasis or the state of cancer cachexia.
Liver cancer-related molecules were found in non-secretory
perfusate proteins
The main diseases in which the non-secretory proteins
participated were liver hyperplasia/hyper-proliferation, liver
hepatitis, liver steatohepatitis, liver steatosis and hepatocel-
lular carcinoma (Figure 4B). These proteins included PAK1,
SOD1, BZW1, IQGAP1, GSTO1, MAT1A and FASN.
Certain cancer-related pathways were over-represented,
such as the PI3, Ras, EGF, FGF and angiogenesis pathways
(data not shown). The proteins involved in these pathways
were PAK1, Grb2, Ywhab and Ppp2r1a. Most of these
proteins showed a higher relative abundance in cancer
perfusates and may be involved in metastasis.
Certain differentially expressed perfusate proteins have
been reported to be associated with metastasis
Some proteins, exhibiting an increased relative abundance
in the model perfusate, have been already reported to
be associated with cancer metastasis, such as Rpl21
[16], Emilin1 [17], Eif3s2 [18,19], Echs1 [20] and CtsD
[21-24]. The relative abundance of CtsD was 5.6-fold
elevated in the perfusates from the livers metastasized
by Walker-256 tumor cells. CtsD is a lysosomal enzyme,
which was reported to be secreted by the breast cancer cells
[21,22]. It was also involved in the metastasis of breastcancer and was an independent prognostic biomarker
for the cancer [23,24].
Validation of differentially expressed perfusate proteins
via Western blotting using plasma
Three proteins were chosen for Western blot analysis:
Beta-2-microglobulin (B2-M), Fibroblast growth factor 21
(FGF 21) and 14-3-3 protein α/β (Ywhab). The plasma for
the validation studies was collected from another 8 pairs
of model and control rats. Each rat’s plasma was collected
at three time-points: on days 0, 6 and 12 (before surgi-
cal inoculation and on the sixth and twelfth days after
inoculation, respectively). An equal volume of plasma
from each rat was loaded onto a gel and analyzed via
Western blotting.
All three proteins were detected in plasma by Western
blotting, as shown in Figure 5. Ywhab increased 3.7-fold
in the model plasma, consistent with the results from the
model perfusates (3.5-fold increased). As a member of the
14-3-3 protein family, Ywhab plays a key role in cellular
proliferation and oncogenic transformation [25]. This result
indicated that Ywhab may participate in liver metastasis
and could be a potential biomarker for this disease.
However, the change direction of B2-M and FGF 21 in
the model plasma was opposite to that in the model perfus-
ates (Figure 5 and Additional file 2: Table S3): the relative
abundance of these proteins was decreased in perfusates,
whereas it was increased in plasma. It is likely that these
proteins are not liver-specific proteins and can be secreted
by other organs [26,27], which may mask their decreased
abundance in the liver. These results indicate that liver
Figure 5 Validation of differentially expressed perfusate proteins in plasma. Beta-2-microglobulin (B2-M), Fibroblast growth factor 21
(FGF 21) and 14-3-3 protein α/β (Ywhab) were chosen for validation by Western blotting. The plasma was collected at three time-points from
each model rat: on days 0, 6 and 12 (before the surgical inoculation and on the sixth and twelfth day after inoculation, respectively). Equal
volumes of plasma were loaded into a gel and analyzed by Western blotting. The change direction in the relative abundance of 14-3-3 protein
α/β in the perfusates was the same as in the plasma, whereas the change direction in the relative abundance of the B2-M and FGF 21 proteins
was opposite to that in the plasma.
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to liver-specific proteins.
In addition, perfusion conditions cannot entirely mimic
true in-vivo conditions and may cause stress or ischemia-
related injuries, which might affect the relative abundance
of certain proteins in the perfusate. Thus, some proteins
identified as being differentially expressed in perfusates may
result from perfusion, rather than disease-related perturb-
ation. And such false-positive identifications should there-
fore be ruled out by further validation in plasma or serum.
Conclusions
In this study, 86 differentially expressed proteins were
identified in perfusates from isolated livers metastasized
by Walker-256 tumor cells. Functional analysis of the
differentially expressed proteins via IPA showed that
liver-associated immune function was suppressed by
the metastasis of these cells. Proteins associated with
liver metastasis were identified in perfusates. Ywhab
was among these proteins, and its differential expression in
plasma was further validated by Western blotting. The re-
sults shown in this study demonstrate the value of utilizing
liver perfusates in biomarker discovery for liver diseases.
Methods
Establishment of the metastasized model
Walker-256 tumor cells were derived from rat mammary
gland carcinosarcomas. These cells have been widely
used in cancer studies [7-9]. In the present study, a
model of liver metastasis was generated via inoculation
of Walker-256 tumor cells into the spleens of maleSprague–Dawley (SD) rats, as described previously [10].
The control rats were subjected to the same surgical
procedure as the model rats but were injected with saline
solution instead of the tumor cells. This study was carried
out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the
National Institutes of Health. The protocol was approved
by the Institutional Animal Care Use & Welfare Committee
of Institute of Basic Medical Sciences (Permit Number:
ACUC-A02-2011-046). All surgery was performed under
sodium pentobarbital anesthesia, and all efforts were made
to minimize suffering.
Isolated rat liver perfusion
On the 11-13th day after inoculation with tumor cells,
the model and control rats were subjected to isolated
liver perfusion. The procedure for isolated liver perfusion
was similar to that described in a previous publication [3].
The perfusion conditions were in accordance with
the standards proposed by Bessems [5]. The perfusate
medium was freshly prepared Krebs/Henseleit- bicarbonate
buffer (pH 7.4) saturated with a mixture of oxygen and
carbon dioxide (95:5). Perfusion flow was mantained at a
rate of 3 ml/min.g liver weight. The perfusion temperature
was maintained at 37°C.
Perfusate sample preparation
A total of 10 perfusates were collected, from 5 model
rats and 5 normal control rats (Additional file 1: Table S1).
The perfusate proteins were extracted via acetone pre-
cipitation [3]. The protein extracts were then subjected
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amounts of protein derived from five individual rats in
the same group (model or control) were mixed together,
resulting in two pooled perfusate samples: A model perfus-
ate mixture and a control perfusate mixture.
Mass spectrometry analysis
The proteins in the two pooled perfusate samples were
reduced, alkylated and trypsin-digested as described previ-
ously [29]. The tryptic peptides were subsequently desalted
via solid-phase extraction (Oasis column, Waters, Inc.) and
dried by vacuum evaporation. The dried peptides were
resuspended in an aqueous solution containing 0.1% formic
acid. In each run, 25 μg of the tryptic peptides was loaded
into a 0.32 × 100 mm Polysulfoethyl A (5 μm, 300 Å,
PolyLC, Inc.) strong cation exchange (SCX) column and
separated into six fractions using the following elution
steps: 12.5 mM, 25 mM, 50 mM, 75 mM, 125 mM and
1 M ammonium acetate. Each SCX fraction was loaded
in-line onto a peptide trap and then resolved using a
0.1 × 150 mm Magic C18AQ reverse phase column
(Michrom Bioresources, Inc.) with the Agilent 1200
HPLC system (Agilent, Inc.). Separation of the peptides
was performed at 500 nL/min and was coupled with online
analysis via tandem mass spectrometry using an LTQ
XL ion trap mass spectrometer (Thermo Finnigan, Inc.)
equipped with a Michrom nanospray ionization source
(Michrom Bioresources, Inc.). The elution gradient for
the reverse phase column ranged from 95% mobile phase A
(2% acetonitrile, 0.1% formic acid, 97.9% water) to 40%
mobile phase B (10% water, 0.1% formic acid, 89.9%
acetonitrile) over 210 minutes. Peptide ions were detected
in a survey scan from 400–2000 amu (1 μscan), followed
by seven data-dependent MS/MS scans (1 μscan, isolation
width of 2 m/z, 35% normalized collision energy, dynamic
exclusion for 1 minute). Five technical replicate analyses
were performed for each pooled perfusate sample.
All MS/MS spectra were searched against the rat IPI 3.49
protein sequence database (40,131 entries) using SEQUEST
algorithm-based Bioworks 3.3.1 (Thermo Finnigan, Inc.).
The search parameters were set as follows: precursor mass
tolerance, ±2.0 amu; fragment mass tolerance, ±1.0 amu;
tryptic cleavage only at lysine or arginine, with up to
two missed cleavage sites allowed; and a static modifi-
cation of +57 amu on cysteine. The search results were
further processed with the Trans-Proteomic Pipeline
(TPP) (Institute for Systems Biology). The SEQUEST
results were validated using PeptideProphet [30], which
also calculates the probability of peptide identification.
ProteinProphet [31] was applied to assemble the peptides
into proteins and calculate the probability of protein
identification. The probability of protein identification
was calculated based in part on the peptide probability and
the SEQUEST Xcorr score [31]. Only proteins identifiedwith a probability >0.9 were considered for further analysis,
as this cutoff resulted in a calculated false discovery rate
(FDR) of approximately 1%.
Spectral counting
The spectral count weight (SCW, the proportion of one
protein’s spectral count compared to the total spectral
count for one MS analysis) was used to estimate the
relative abundance of one protein in each sample. Each
of the pooled perfusate samples from the model and
control rats was subject to five MS analyses, as described
above. Ten sets of SCW values were obtained for every
protein identified in the ten MS analyses. The SCW
value was set to zero when a protein was not identified
in an MS analysis. The difference between a protein’s
SCW values in the model and control groups was analyzed
for statistical significance with Student’s t-test using
SPSS software (version 11.5). A p-value < 0.01 was set
as the cut-off for statistical significance.
After quantification, three selection criteria were applied
to increase the credibility of protein identification and
quantification. First, the proteins identified by a single
peptide were excluded, regardless of how many spectra
were identified. Second, for proteins showing an elevated
relative abundance in the model perfusates, we required
that they be identified in all five MS analyses performed
in the model perfusates, and for proteins showing an
elevated relative abundance in control perfusates, we
required that they be identified in all five MS analyses
conducted in the control perfusates. Third, we selected
proteins showing fold changes > 2.5 as confidently dif-
ferentially expressed proteins.
Computational prediction of secretory proteins
SignalP 3.0 [32] (http://www.cbs.dtu.dk/services/SignalP/)
was used to predict the N-terminal signal peptides for
classically secreted proteins. Two algorithms in SignalP,
including neural network algorithm and hidden Markov
model, were employed to predict the signal peptides. We
considered the proteins that were positively predicted by
both algorithms to be secreted.
Validation of differentially expressed perfusate proteins
in plasma by Western blotting
A 20 μl aliquot of plasma collected for validation was first
diluted in 1 mL of PBS. Then, the same volume of diluted
plasma from every group was loaded onto SDS-PAGE gels
and transferred to PVDF membranes (Millipore, 0.22 μm)
with a transfer apparatus (Bio-Rad). The membranes were
first blocked in a 5% BSA/TBS solution for 1 h at room
temperature. All antibodies were purchased from Abcam.
The primary antibodies were diluted in a 1% BSA/TBS so-
lution to the ratios indicated in the specific instructions
from Abcam, and the membranes were then incubated
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then incubated with the secondary antibodies, diluted
1:10,000 in a 1% BSA/TBS solution, for 2 h at room
temperature. The protein signals were detected and
quantified with the AlphaEaseFC system.
Additional files
Additional file 1: Table S1. Lists general characteristics of the
perfusates. Table S2 lists protein numbers and total spectral counts
identified in each replicate analysis. Figure S1 shows serum
contamination was low in the perfusates. Image 1–3 shows macroscopic
and microscopic of tumor tubercles.
Additional file 2: Table S3. Lists all the differential proteins identified
in perfusates.
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